PACTR202311877246623已完成3 期
Post -transplantation Cyclophosphamide as Graft Versus Host Disease prophylaxis in Children with ß-Thalassemia Major undergoing Hematopoietic Stem Cell Transplantation
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 Year(s) 至 5 Year(s)（—）
- 性别
- All
入选标准
- •Children with ß-thalassemia major (Pesaro class I, II) undergoing allogeneic peripheral blood stem cell transplantation from matched related donor aged 2- 18 years.
排除标准
- •i.Children with ß-thalassemia major (Pesaro class III).
- •ii.Conditions with contraindication to cyclophosphamide use as ( systemic infections , uric acid kidney stones , inflammation of bladder with hemorrhage , obstruction of any part of the urinary tract , bloody urine , kidney disease with likely reduction in kidney function , children with a previous hypersensitivity to it .
研究者
相似试验
进行中（未招募）
1 期
High doses of cyclophosphamide for prophylaxis of GVHD in patients undergoing allogeneic transplantatioEUCTR2017-003530-85-ITGITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA78
已完成
不适用
Posttransplantation cyclophosphamide and tacrolimus for prevention of Graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from HLA matched sibling or unrelated donor: a single center prospective phase II study (OCU16-1)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Malignant lymphoma(ML)JPRN-UMIN000023890Osaka City University39
尚未招募
2 期
Thalassemia study with stem cellsCTRI/2018/07/014826Christian Medical College Vellore
进行中（未招募）
1 期
Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem celltransplantation for multiple myeloma. A phase II study.Multiple myelomaEUCTR2016-002557-38-DEniversity Medical Center Hamburg-Eppendorf50
已完成
2 期
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related DonorsHematological MalignanciesNCT01349101Sidney Kimmel Cancer Center at Thomas Jefferson University78